Charge Effects and Transient Simulation of p-HEMT Meander Gate Switches

Holm, M.A.; Cameron, N.; Brookbanks, D.M.

doi:10.1109/emicc.2006.282658

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, upregulators of ABCA1 are under active study. ABCA1 is known to be under regulation by the LXR signal transduction pathway, and LXR agonists are in development as potential ABCA1 upregulators, as documented in the general literature [106][107][108][109][110][111] and in published patents [112][113][114]. Abelman et al have identified and published a patent on quinoline derivatives raising ABCA1 levels in mammalian cells, although it is unclear whether these compounds act via the LXR pathway [115].…”

Section: Synthesismentioning

confidence: 99%

Genetics of Cholesterol and Lipoprotein Metabolism

Samuels¹

2007

PRC

View full text Add to dashboard Cite

The goal of drugs is to modulate the activity of particular gene products in order to change the physiological state of an organism from disease to health. Because of the complexity of development and metabolism, it is difficult to extrapolate from in vitro experimental results using purified reagents, to predict the actual change in behavior of an entire biological system in vivo. Metabolic control analysis provides a theoretical framework for understanding the basis of this apparent paradox. In practice, genetics provides a unique opportunity to observe the behavior of whole systems in the presence of different amounts of a particular gene product, resulting from varying genomic sequences of alleles governing the expression or activity of that gene product. This is most evident in the case of monogenic disorders, in which severe mutations in a gene lead to clear effects on gene product activity, and strong causal genotype/phenotype correlations can be inferred. Among the many therapeutic targets currently in development for treatment of dyslipidemia, a major risk factor for cardiovascular disease, there is particular interest in those targets whose coding genes are associated with molecularly characterized monogenic human conditions. Herein a selection of these genetic disorders, especially those involving HDL and LDL cholesterol, is discussed in the context of ongoing or potential therapeutic development programs. This article also includes recent patent review coverage.

show abstract

Section: Synthesismentioning

confidence: 99%

Genetics of Cholesterol and Lipoprotein Metabolism

Samuels¹

2007

PRC

View full text Add to dashboard Cite

show abstract

“…AstraZeneca reported a series of pyrrole-2,5-dithione derivatives as LXR modulators [76], where compounds 5 and 6 displayed EC 50 of 0.09 and 0.14 μmol/l in coactivator recruitment assays, respectively.…”

mentioning

confidence: 99%

HDL Elevation and Lipid Lowering Therapy: Current Scenario and Future Perspectives

Chhabria¹,

Suhagia²,

Brahmkshatriya

2007

PRC

View full text Add to dashboard Cite

High density lipoprotein (HDL) has proven its role in reverse cholesterol transport and cellular cholesterol efflux thus acting as a protective factor against atherogenic cardiovascular diseases. The article focuses primarily on structure and function of genes influencing HDL metabolism. Various novel targets involve liver X receptor, retinoid X receptor, peroxisome proliferators activated receptor agonists and apoA-I mimetics. New molecules targeting these nuclear receptors are described. Phospholipid transfer protein and scavenger receptor B1 are also attractive targets in HDL metabolism. ATP-Binding Cassette transporter A1 and several lipases also play a crucial role in HDL metabolism and are very useful target for atherogenic dyslipidemia. Cholesteryl ester transfer protein inhibitors have shown great promise as possible drug candidates of future. Notably, JTT-705 (Japan Tobacco, Roche) is of great interest in spite of withdrawal of torcetrapib. Considering modest effect of currently available therapeutic options on HDL, these novel HDL elevating targets are doubtlessly the target for future atherosclerotic intervention.

show abstract